aetiologies. Pattern of interstitial lung diseases widely varies geographically. Data on epidemiology and pattern of ILDs are limited in Sri Lanka.
4 (28.5%) diffuse systemic sclerosis, 2 (14.2%) limited systemic sclerosis, 1 (7.1%) overlap syndrome, 1 (7.1%) mixed connective tissue disease and 1 (7.1 %) polymyositis. Furthermore, 7 (12.0%) were classified as interstitial pneumonia with autoimmune features (IPAF). There was one case of ILD secondary to amiodarone toxicity. Fourteen (24.1%) of total cohort were diagnosed with hypersensitivity pneumonitis and 1 (1.7%) had sarcoidosis. Background and Aims: Serum KL-6 is known to be a useful biomarker for the diagnosis and assessment of the disease activity in idiopathic pulmonary fibrosis (IPF). However, some patients with untreated IPF present with a serial decline in their serum KL-6 levels, despite showing clinical progression. The aim of the present study was to evaluate the association between the time course of the serum KL-6 levels and the clinical course of patients with untreated IPF.
Conclusion
Methods: We conducted a retrospective study of 59 patients who met the diagnostic criteria for IPF, who regularly underwent laboratory tests including the measurement of KL-6 and pulmonary function tests, and who were untreated during the follow-up period.
Results: The baseline forced vital capacity (FVC) %predicted among non-survivors (n = 29) was lower than that among survivors (n = 30, P = 0.02). The baseline levels of serum KL-6 among non-survivors were higher than those among survivors (P = 0.024). The rates of decline in comparison to the baseline FVC values were comparable between survivors and non-survivors; however, the rates of change in comparison to the baseline KL-6 levels were heterogeneous in both survivors and nonsurvivors, and the KL-6 levels of the non-survivors were observed to decline significantly more frequently in comparison to the survivors (P = 0.001).
Conclusion:
A decline in the serum KL-6 levels of patients with untreated IPF does not mean that the disease activity has subsided. Serum KL-6 levels can naturally decline in association with disease progression. image, lung function, arterial blood gas, modified medical research council (mMRC) dyspnea scale and 6-min walk test (6MWT) were compared before and after WLL. Meanwhile, review the complication before and after this treatment to evaluate the safety.
Results: 25 patients with PAP undergoing WLL were included in this study. There were 13 males and 12 females with an average age of 42.5 years (22~63 years). 20 patients completed MMRC scores before and after WLL and improved significantly after WLL (1.1 AE .64 vs 2.1 AE .37, P < 0.05). The SaO 2 , PaO 2 , and oxygenation index at 1 h after extubation were not significantly improved, but were significantly improved at 1 day after WLL. After WLL, lung function testing items such as FEV1%, FVC, and DLCO% were significantly improved. Transient hypoxemia occasionally occurs in WLL treatment. All patients had cough and sputum with varying degrees after operation. Among them, 3 cases had low fever after operation and were cured after antibiotic therapy. No serious incident occurred.
